Journal of Formulation Science & Bioavailability

In recent years, drug delivery systems have seen remarkable advancements, driven by the need for targeted and controlled drug release. Among these innovations, the use of Red Blood Cells (RBCs) as carriers for drug delivery has garnered significant attention. RBCs are ideal candidates due to their biocompatibility, long circulatory half-life and the potential to encapsulate a variety of therapeutic agents. Two promising strategies for drug delivery involving RBCs are osmosis-based methods: hypotonic swelling and isotonic shrinkage. In this article, we will explore and evaluate the efficacy of these two osmosis-based strategies in RBC drug delivery systems. Before delving into the evaluation of hypotonic swelling and isotonic shrinkage, it's essential to understand the underlying principles of osmosis-based drug delivery within RBCs. The field of drug delivery has witnessed significant advancements over the years, with researchers constantly exploring innovative methods to improve the targeted delivery of therapeutic agents. One promising avenue is the use of Red Blood Cells (RBCs) as drug carriers due to their unique properties, such as long circulation times, biocompatibility and the potential to evade the immune system. Among the various strategies for loading drugs into RBCs, osmosis-based methods have gained prominence. In this article, we will evaluate the efficacy of two osmosis-based strategies for drug delivery systems using RBCs.

Pediatric patients often present unique challenges when it comes to medication administration. Carvedilol, a widely used beta-blocker for the management of various cardiovascular conditions, is no exception. While it is typically available in tablet form for adult patients, formulating a safe, effective and palatable liquid formulation for pediatric use can be a complex and demanding task. In this article, we will explore the formulation and development challenges faced in creating a pediatric-friendly carvedilol liquid. Children can suffer from a wide range of cardiovascular conditions, such as hypertension, heart failure, or arrhythmias, for which carvedilol may be a suitable treatment option. However, administering tablets to pediatric patients can be problematic. Children often struggle to swallow pills and the dosing accuracy for tablets can be challenging. Furthermore, many pediatric patients require customized dosing, which is more easily achieved with liquid formulations.

Acute Myeloid Leukemia (AML) is a complex and aggressive form of blood cancer characterized by the rapid growth of abnormal white blood cells in the bone marrow. Despite significant advancements in cancer research and treatment, AML remains a challenging disease to combat. Standard chemotherapy regimens have limited efficacy, and many patients face relapse or resistance to treatment. To address these challenges, researchers are turning to innovative approaches such as transcriptional analysis to identify synergistic drug combinations for more effective AML treatment. Transcriptional analysis, also known as gene expression profiling, offers a comprehensive view of the genetic and molecular landscape of AML cells. By examining the activity of thousands of genes simultaneously, researchers can gain valuable insights into the underlying mechanisms of AML and identify potential therapeutic targets. This article explores the role of transcriptional analysis in AML research and its potential for uncovering synergistic drug combinations that can improve patient outcomes.

Cancer continues to be a formidable challenge in the realm of medical science, with solid tumors posing particular difficulties in treatment. These tumors are characterized by a dense microenvironment that can hinder the delivery of anticancer drugs to their intended targets. To address this challenge, scientists have been exploring innovative drug delivery systems, and one promising approach is the use of injectable Nanogels. Injectable Nanogels are a versatile and highly effective method for delivering anticancer drugs precisely to solid tumors, offering the potential for enhanced therapeutic outcomes while minimizing systemic side effects. In this article, we will explore the concept of injectable Nanogels, their unique advantages, and their applications in targeting solid tumors with anticancer drugs.